The CD38 decreased expression driven by daratumumab treatment may be related at least to the following additional mechanisms: (i) clustering of CD38 molecules into distinct polar aggregates, which can subsequently be released as tumor-derived microvesicles [89]; (ii) direct internalization of CD38; and (iii) active transfer of CD38-daratumumab complexes from tumor cell membrane to monocytes and granulocytes [90]. Here, CD38 is linked to neoplasm.